器官移植2025，Vol.16Issue(4)：516-525,10.DOI:10.12464/j.issn.1674-7445.2025075
人脐带间充质干细胞及其衍生物治疗缺血-再灌注损伤的研究进展
Research progress on the treatment of ischemia-reperfusion injury with human umbilical cord mesenchymal stem cells and their derivatives
摘要
Abstract
Ischemia-reperfusion injury(IRI)can lead to organ dysfunction and tissue necrosis in the liver,kidney,myocardium and spinal cord,and there is currently a lack of effective treatment options.Human umbilical cord mesenchymal stem cell(HUC-MSC)and their derivatives have anti-inflammatory,anti-apoptotic,reactive oxygen species scavenging,mitochondrial and endothelial function improvement properties,and are ideal gene therapy carrier cells,providing new possibilities for the treatment of IRI in different organs.This article reviews the concept and mechanisms of IRI,the biological characteristics of HUC-MSC and their derivatives and their comparison with mesenchymal stem cells from other sources,and the mechanisms of HUC-MSC in treating IRI in different organs.It also summarizes and analyzes the advantages and disadvantages of HUC-MSC in protecting different organs from IRI,and prospects future research directions to explore more valuable research paths.关键词
人脐带间充质干细胞/缺血-再灌注损伤/外泌体/细胞外囊泡/间充质干细胞/细胞凋亡/线粒体功能/氧化应激Key words
Human umbilical cord mesenchymal stem cell/Ischemia-reperfusion injury/Exosome/Extracellular vesicle/Mesenchymal stem cell/Apoptosis/Mitochondrial function/Oxidative stress分类
医药卫生引用本文复制引用
乜茹,段云龙,庞明泉,王志鑫,樊海宁..人脐带间充质干细胞及其衍生物治疗缺血-再灌注损伤的研究进展[J].器官移植,2025,16(4):516-525,10.基金项目
国家临床重点专科建设项目(青卫健办2023-125号) （青卫健办2023-125号）
2022年青海科技厅科技计划项目(青科发规2022-84号) （青科发规2022-84号）
